<DOC>
	<DOCNO>NCT02464046</DOCNO>
	<brief_summary>The primary purpose study investigate effect JNJ-42847922 ( change versus placebo ) sleep efficiency ( SE ) measure polysomnography ( PSG ) single multiple dose administration participant insomnia disorder without psychiatric comorbidity .</brief_summary>
	<brief_title>Study Evaluate Efficacy , Safety Tolerability JNJ-42847922 Participants With Insomnia Disorder Without Psychiatric Comorbidity</brief_title>
	<detailed_description>This multi-center , randomize ( study medication assign participant chance ) , placebo-controlled , double-blind ( neither physician participant know identity assign treatment ) , 2-way cross-over study JNJ-42847922 participant insomnia disorder without psychiatric comorbidity . The study consist follow phase : screening ( 28 day prior Day 1 ) , double-blind treatment phase ( consist 5-day treatment , either JNJ-42847922 placebo subsequent 2-treatment period , separate washout period 5 9 day ) , follow-up examination ( 7 14 day last dose administration ) . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<criteria>Healthy male female participant age 18 65 year , inclusive Body mass index ( BMI ) 18 30 kilogram per square meter ( kg/m^2 ) inclusive ( BMI = weight/height^2 ) Insomnia Severity Index ( ISI ) score equal ( &gt; = ) 15 screen Insomnia : screening participant report difficulty sleep onset sleep maintenance . Insomnia furthermore objectively establish prior enrollment per PSG record 3 consecutive night . Participants sleep 3 consecutive night sleep center . First second night data use exclude participant restless leg syndrome , apnea , parasomnias sleep disorder . On second third night participant require meet objective inclusion criterion : 2night mean LPS &gt; =30 minute night &lt; 20 minute , night TST &lt; =6 hour wake sleep onset ( WASO ) &gt; 30 minute Participants must healthy / medically stable basis clinical laboratory test , medical history , vital sign , 12lead electrocardiogram ( ECG ) perform screen baseline Participant current signs/symptoms , liver renal insufficiency ; hypothyroidism hyperthyroidism , significant cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , hematologic , rheumatologic , metabolic disturbance . Participants noninsulin dependent diabetes mellitus adequately control ( insulin ) may participate study History epilepsy fit unexplained blackout Clinically significant abnormal value hematology , clinical chemistry urinalysis screen admission Clinically significant abnormal physical neurological examination , vital sign 12lead ECG screen baseline Smoking &gt; =10 cigarettes/daily Insomnia relate restless leg syndrome , sleep breathing disorder , narcolepsy , obstructive sleep apnea/hypopnea , central sleep apnea , sleeprelated hypoventilation , circadian rhythm sleepwake disorder , substance/medicationinduced sleep disorder parasomnias Nightshift worker significantly shift diurnal activity pattern</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Insomnia</keyword>
	<keyword>JNJ-42847922</keyword>
	<keyword>Placebo</keyword>
</DOC>